nach oben

Clinical Rheumatology

Erschienen in:

02.09.2023 | ORIGINAL ARTICLE

The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever

verfasst von: Elif Arslanoglu Aydin, Esra Baglan, Nesibe Gokce Kocamaz, İlknur Bagrul, Serife Tuncez, Semanur Ozdel

Erschienen in: Clinical Rheumatology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction/objectives

This study aimed to evaluate the effect of canakinumab on growth parameters in children with familial Mediterranean fever (FMF).

Method

We conducted a retrospective analysis of 946 pediatric FMF patients followed in our center, of whom 37 were treated with canakinumab for at least three doses. Patients were assessed for demographic, clinical, and genetic characteristics. Data of height and weight percentiles and Z scores were recorded before and after canakinumab treatment and compared.

Results

The study group comprised 37 FMF patients with treated canakinumab. The median age (IQR) at diagnosis and canakinumab initiation was 3.0 (2.0–4.3) years and 7.0 (3.6–10.1) years, respectively. The median weight scores and mean body mass index (BMI) values significantly increased after canakinumab treatment. There was no change in height scores following canakinumab treatment.

Conclusion

Canakinumab treatment has improved off body weight and BMI parameters of FMF patients by controlling disease activity and inflammation.

Key Points

• To our knowledge, few studies in the literature evaluate the growth parameters of canakinumab treatment in FMF children.

• Canakinumab treatment has been shown to affect body weight and BMI positively.

• Long-term studies are needed for its effects on height.

Sönmez HE, Batu ED, Özen S (2016) Familial Mediterranean fever: current perspectives. J Inflamm Res 17:13–20. https://doi.org/10.2147/JIR.S91352CrossRef

Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al (2011) Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 34:755–768. https://doi.org/10.1016/j.immuni.2011.02.020CrossRefPubMedPubMedCentral

Akpolat T, Özkaya O, Özen S (2012) Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene 492:285–289. https://doi.org/10.1016/j.gene.2011.10.012CrossRefPubMed

Özen S, Sag E, Ben-Chetrit E, Gattorno M, Gül A, Hashkes PJ, Kone-Paut I, Lachmann HJ, Tsitsami E, Twilt M, Benedetti F, Kuemmerle-Deschner JB (2021) Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford) 60:3799–3808. https://doi.org/10.1093/rheumatology/keaa863CrossRefPubMed

Dinarello CA, Wolfe SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial Mediterranean fever. N Engl J Med 291:934–937. https://doi.org/10.1056/NEJM197410312911804CrossRefPubMed

Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:e474–e483. https://doi.org/10.1542/peds.2006-1434CrossRefPubMed

van der Hilst JCH, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75–80. https://doi.org/10.2147/BTT.S102954CrossRefPubMedPubMedCentral

Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S (2020) The use of interleukine-1 inhibitors in familial Mediterranean fever patients: a narrative review. Front Immunol 11:971. https://doi.org/10.3389/fimmu.2020.00971CrossRefPubMedPubMedCentral

Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A et al (2009) A new set of criteria for the diagnosis of Clin Rheumatol familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398. https://doi.org/10.1093/rheumatology/ken509CrossRefPubMed

10.

Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75:644–651. https://doi.org/10.1136/annrheumdis-2015-208690CrossRefPubMed

11.

Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F et al (2015) Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 7:280–293. https://doi.org/10.4274/jcrpe.2183CrossRefPubMedPubMedCentral

12.

Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977. https://doi.org/10.1002/art.1780340806CrossRefPubMed

13.

Başaran Ö, Uncu N, Çelikel BA, Taktak A, Gür G, Cakar N (2015) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 25:621–624. https://doi.org/10.3109/14397595.2014.987437CrossRefPubMed

14.

Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, Aydın AK, Dasdemir S, Turanlı ET, Buyru N, Kasapcopur O (2018) Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int 38:67–74. https://doi.org/10.1007/s00296-017-3796-0CrossRefPubMed

15.

Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, Erten S (2017) Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol 27:350–355. https://doi.org/10.1080/14397595.2016.1194510CrossRefPubMed

16.

Yücel BB, Aydog O, Nalcacioglu H, Yılmaz (2021) Effectiveness of canakinumab treatment in colchicine resistant familial Mediterranean fever cases. Front Pediatr 9:710501. https://doi.org/10.3389/fped.2021.710501CrossRefPubMedPubMedCentral

17.

Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, Gür G, Bülbül M (2018) Canakinumab treatment in children with familial Mediterranean fever: report from a single center. Rheumatol Int 38:879–885. https://doi.org/10.1007/s00296-018-3993-5CrossRefPubMed

18.

Sag E, Akal F, Atalay E, Akca UK, Demir S, Demirel D, Batu ED, Bilginer Y, Ozen S (2020) Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford) 59:3324–3329. https://doi.org/10.1093/rheumatology/keaa121CrossRefPubMed

19.

Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31:633–640. https://doi.org/10.1007/s00467-015-3249-5CrossRefPubMed

20.

MacRae VE, Wong SC, Farquharson C, Ahmed SF (2006) Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med 18:1011–1018. https://doi.org/10.3892/ijmm.18.6.1011CrossRefPubMed

21.

Sozeri B, Yilmaz E, Mir S, Berdeli A (2011) Effect of colchicine-resistant familial mediterranean fever on growth parameters. Arch Rheumatol 26:1–6

22.

Türkmen M, Soylu OB, Kasap B, Güneş S, Tüfekçi O, Soylu A, Erçal D, Kavukçu S (2008) Growth in familial mediterranean fever: effect of attack rate, genotype and colchicine treatment. J Pediatr Endocrinol Metab 21:789–792. https://doi.org/10.1515/jpem.2008.21.8.789CrossRefPubMed

23.

Yoldaş TÇ, Çakar N, Başaran Ö, Acar B, Uncu N, Çaycı FŞ (2016) The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever. Clin Rheumatol 35:1603–1607. https://doi.org/10.1007/s10067-015-3077-9CrossRefPubMed

24.

Kişla Ekinci RM, Balci S, Akay E, Doğruel D, Altintaş DU, Yilmaz M (2019) Disease severity and genotype affect physical growth in children with familial Mediterranean fever. Arch Rheumatol 34:288–293. https://doi.org/10.5606/ArchRheumatol.2019.7198CrossRefPubMedPubMedCentral

25.

Pinchevski-Kadir S, Gerstein M, Pleniceanu O, Yacobi Y, Vivante A, Granat OE, Spielman S, Oz RS, Tirosh I (2023) Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF. Pediatr Rheumatol Online J 21:4. https://doi.org/10.1186/s12969-022-00784-6CrossRefPubMedPubMedCentral

26.

Balci S, Ekinci RMK, Dogruel D, Altintas DU, Yilmaz M (2020) Growth parameters of Turkish children with an autoinflammatory disease before and after canakinumab treatment. Indian Pediatr 57:637–640. https://doi.org/10.1007/s13312-020-1892-9CrossRefPubMed

27.

Karabulut Y, Gezer HH, Duruöz MT (2022) Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment. Rheumatol Int 42:81–86. https://doi.org/10.1007/s00296-021-04997-yCrossRefPubMed

28.

Berdeli A, Şenol Ö, Talay G (2019) Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine. Eur J Rheumatol 6:85–88. https://doi.org/10.5152/eurjrheum.2019.18190CrossRefPubMedPubMedCentral

29.

Tomokawa T, Koga T, Endo Y, Michitsuji T, Kawakami A (2022) Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: a single-centre observational study. Mod Rheumatol 32:797–802. https://doi.org/10.1093/mr/roab048CrossRefPubMed

30.

Gülez N, Makay B, Sözeri B (2020) Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients. Mod Rheumatol 30:166–171. https://doi.org/10.1080/14397595.2018.1559488CrossRefPubMed

31.

Kacar M, Savic S, van der Hilst JCH (2020) The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever: a systematic review of the literature. J Inflamm Res 13:141–149. https://doi.org/10.2147/JIR.S206204CrossRefPubMedPubMedCentral

Titel: The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever
verfasst von: Elif Arslanoglu Aydin
Esra Baglan
Nesibe Gokce Kocamaz
İlknur Bagrul
Serife Tuncez
Semanur Ozdel
Publikationsdatum: 02.09.2023
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 1/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06752-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction/objectives

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis

Low utilization of statins in patients with dermatomyositis/polymyositis and hyperlipidemia: a multicenter USA-based study (2013–2023)

Decreased expression of TIGIT on CD14 + monocytes correlates with clinical features and laboratory parameters of patients with primary Sjögren’s syndrome

Inflammatory rheumatic diseases and the risk of drug use disorders: a register-based cohort study in Sweden

Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance